2024, a landmark event in precision oncology, took place in Abu Dhabi, United Arab Emirates (UAE), on the 1 st and 2 nd of March 2024; marking a significant collaboration between the Worldwide Innovative Network (WIN) Consortium and Burjeel Holdings.This annual global congress of the WIN Consortium brought together physicians, researchers, and scientists from 30 countries to explore the latest advancements in precision oncology, with the ultimate goal of improving cancer patient care and outcomes worldwide.The call for abstracts attracted 51 submissions with 42 accepted as posters and 3 as oral presentations.This publication features 34 of the accepted abstracts.The WIN Consortium, a non-profit association headquartered in France, unites 31 world-class academic medical centers, healthcare industries, research organizations, and patient advocacy groups from 18 countries, aligned to launch cancer trials using omic platforms to bolster precision oncology across the world.BMC -Burjeel Medical City, the flagship facility of Burjeel Holdings, is the first member from the UAE and Gulf Cooperation Council countries to join the WIN Consortium.Abu Dhabi was selected as the city to host this year's congress, marking its inaugural occurrence outside of its traditional place in European.The congress featured a meticulously curated program, including interactive elements that illustrate the principles and best practices of precision cancer treatment including dedicated sessions for precision genomics, precision immunotherapy, precision radiotherapy, precision communityomics, a molecular tumor board, and a precision diagnostics panel.Under the theme 'Precision and Molecular Oncology: Caring for Patients and Future Generations,' the congress kicked off with a grand opening featuring 2018 Nobel Laureate,
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: